Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: A report of POG study 9296

被引:17
作者
Winter, SS
Holdsworth, MT
Devidas, M
Raisch, DW
Chauvenet, A
Ravindranath, Y
Ducore, JM
Amylon, MD
机构
[1] 1 Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA
[3] Childrens Oncol Grp, Stat Off, Gainesville, FL USA
[4] Clin Res Pharm Coordinating Ctr, Vet Affairs Cooperat Studies Program, Albuquerque, NM USA
[5] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA
[6] Childrens Hosp Michigan, Detroit, MI 48201 USA
[7] Univ Calif Davis, Sacramento, CA 95817 USA
[8] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
关键词
intravenous; 6-mercaptopurine; lymphoblastic lymphoma; methotrexate; PEG-asparaginase; secondary neoplasms; T-ALL; teniposide;
D O I
10.1002/pbc.20429
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. A previous Pediatric Oncology Group (POG) study showed high incidence of secondary acute myelogenous leukemia (AML) in children treated for T-cell acute lymphoblastic leukemia MALL) or higher-stage lymphoblastic lymphoma. To prevent secondary neoplasms, induce prolonged asparagine depletion, and maintain high event-free Survival (EFS) in children with newly diagnosed T-ALL or higher-stage non-Hodgkins lyrnphoma (NHL), we designed this pilot study to determine feasibility and safety of substituting methotrexate/mercaptopurine for teniposide/cytarabine and PEG-asparaginase for native asparaginase. Patients and methods. Forty-five patients were entered, 29 with T-ALL and 16 with higher-stage NHL. Forty-two of 45 patients achieved complete remission (CR), and 27 completed the therapy in continuous CR. Treatment consisted of 4-week induction then 6 weeks consolidation and ten 9-week maintenance cycles. Therapy primarily comprised antimetabolites, anthracyclines, alkylating agents, and asparaginase. Expected chemotherapy duration was 100 weeks. Results. Forty-two of 45 patients achieved CR, and 27 completed therapy. The most common toxicities were Grade 3 or 4 myelosuppression after cyclophosphamide/cytarabine and allergic reactions to asparaginase. Two died of sepsis early in maintenance. Five-year EFS was 68.5% (SE 9.1%) for T-ALL and 81.3% (SE 9.8%) for NHL. Five-year EFS was 73.1 % (SE 6.8%) for the entire cohort. No patients treated entirely on this study developed secondary neoplasms. One patient taken off study for asparaginase toxicity was treated with multiagent therapy that contained teniposide, and died from secondary myelodysplasia (sMDS)/AML. Conclusion. Substituting methotrexate/mercaptopurine for teniposide/cytarabine and PEG-asparaginase for native asparaginase in a dose-intensive regimen was feasible in children and young adults with newly diagnosed T-ALL or higher-stage NHL. EFS was not compromised and secondary neoplasms were decreased.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 59 条
[1]   Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study [J].
Abshire, TC ;
Pollock, BH ;
Billett, AL ;
Bradley, P ;
Buchanan, GR .
BLOOD, 2000, 96 (05) :1709-1715
[2]   Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study [J].
Amylon, MD ;
Shuster, J ;
Pullen, J ;
Berard, C ;
Link, MP ;
Wharam, M ;
Katz, J ;
Yu, A ;
Laver, J ;
Ravindranath, Y ;
Kurtzberg, J ;
Desai, S ;
Camitta, B ;
Murphy, SB .
LEUKEMIA, 1999, 13 (03) :335-342
[3]  
AMYLON MD, 1986, MALIGNANT T CELL OTH, P152
[4]   Secondary myelodysplasia with monosomy 7 arising after treatment for acute lymphoblastic leukemia in childhood [J].
Aquino, VM ;
Schneider, NR ;
Sandler, ES .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (01) :48-50
[5]   COMPARATIVE PHARMACOKINETIC STUDIES OF 3 ASPARAGINASE PREPARATIONS [J].
ASSELIN, BL ;
WHITIN, JC ;
COPPOLA, DJ ;
RUPP, IP ;
SALLAN, SE ;
COHEN, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) :1780-1786
[6]  
Asselin BL, 1999, ADV EXP MED BIOL, V457, P621
[7]   Adhesion molecules involved in the interactions between early T cells and mesenchymal bone marrow stromal cells [J].
Barda-Saad, M ;
Rozenszajn, LA ;
Ashush, H ;
Shav-Tal, Y ;
Ben Nun, A ;
Zipori, D .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (05) :834-844
[8]  
BILLETT AL, 1992, CANCER, V70, P201, DOI 10.1002/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO
[9]  
2-M
[10]  
BUCHANAN GR, 1991, CANCER-AM CANCER SOC, V68, P48, DOI 10.1002/1097-0142(19910701)68:1<48::AID-CNCR2820680110>3.0.CO